MA49047A - Composés inhibiteurs d'ask1 et utilisations associées - Google Patents
Composés inhibiteurs d'ask1 et utilisations associéesInfo
- Publication number
- MA49047A MA49047A MA049047A MA49047A MA49047A MA 49047 A MA49047 A MA 49047A MA 049047 A MA049047 A MA 049047A MA 49047 A MA49047 A MA 49047A MA 49047 A MA49047 A MA 49047A
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitor compounds
- ask1 inhibitor
- associated uses
- ask1
- compounds
- Prior art date
Links
- 229940127254 ASK1 inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762482085P | 2017-04-05 | 2017-04-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49047A true MA49047A (fr) | 2020-02-12 |
Family
ID=63712299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049047A MA49047A (fr) | 2017-04-05 | 2018-04-04 | Composés inhibiteurs d'ask1 et utilisations associées |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US20210087167A1 (fr) |
| EP (1) | EP3606519B1 (fr) |
| JP (1) | JP7196093B2 (fr) |
| KR (1) | KR102665145B1 (fr) |
| CN (1) | CN110730661B (fr) |
| AR (1) | AR111407A1 (fr) |
| AU (1) | AU2018250217B2 (fr) |
| CA (1) | CA3059107A1 (fr) |
| CL (1) | CL2019002810A1 (fr) |
| CO (1) | CO2019011708A2 (fr) |
| CR (1) | CR20190503A (fr) |
| CU (1) | CU20190080A7 (fr) |
| DK (1) | DK3606519T3 (fr) |
| DO (1) | DOP2019000255A (fr) |
| EA (1) | EA201992299A1 (fr) |
| EC (1) | ECSP19078393A (fr) |
| ES (1) | ES2992084T3 (fr) |
| FI (1) | FI3606519T3 (fr) |
| HU (1) | HUE068103T2 (fr) |
| IL (1) | IL269711B (fr) |
| JO (1) | JOP20190221A1 (fr) |
| MA (1) | MA49047A (fr) |
| MX (1) | MX394098B (fr) |
| NI (1) | NI201900102A (fr) |
| NZ (1) | NZ758345A (fr) |
| PE (1) | PE20200009A1 (fr) |
| PH (1) | PH12019502288A1 (fr) |
| PL (1) | PL3606519T3 (fr) |
| PT (1) | PT3606519T (fr) |
| RU (1) | RU2019134679A (fr) |
| SG (1) | SG11201909155VA (fr) |
| SI (1) | SI3606519T1 (fr) |
| TW (1) | TWI779022B (fr) |
| WO (1) | WO2018187506A1 (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6754505B2 (ja) * | 2017-01-22 | 2020-09-09 | 福建広生堂薬業股▲ふん▼有限公司 | Ａｓｋ１阻害剤、その調製方法および使用 |
| AU2018266911C1 (en) | 2017-05-12 | 2022-10-20 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| EP3735404B1 (fr) | 2018-01-02 | 2023-11-29 | Seal Rock Therapeutics, Inc. | Composés inhibiteurs d'ask1 et utilisations associées |
| CN110407806B (zh) * | 2018-04-28 | 2021-08-17 | 深圳微芯生物科技股份有限公司 | 甲酰胺类化合物、其制备方法及其应用 |
| ES3004523T3 (en) | 2018-05-02 | 2025-03-12 | Enanta Pharm Inc | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2020006429A1 (fr) * | 2018-06-28 | 2020-01-02 | Hepatikos Therapeutics, Llc | Inhibiteurs d'isoindolin-1-one ask1 et leurs procédés d'utilisation |
| WO2020041417A1 (fr) | 2018-08-22 | 2020-02-27 | Enanta Pharmaceuticals, Inc. | Inhibiteurs de la kinase 1 régulant le signal d'apoptose contenant un cycloalkyle et leurs procédés d'utilisation |
| WO2020106707A1 (fr) | 2018-11-19 | 2020-05-28 | Enanta Pharmaceuticals, Inc. | Inhibiteurs de la kinase 1 régulant le signal d'apoptose et leurs méthodes d'utilisation |
| US11466033B2 (en) | 2019-03-25 | 2022-10-11 | Enanta Pharmaceuticals, Inc. | Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors |
| CN112409332B (zh) * | 2019-08-23 | 2023-12-08 | 广东东阳光药业股份有限公司 | 三氮唑衍生物及其在药物中的应用 |
| PE20221283A1 (es) | 2019-12-27 | 2022-09-05 | Lupin Ltd | Compuestos triciclicos sustituidos |
| PE20230323A1 (es) | 2020-05-01 | 2023-02-22 | Pfizer | Compuestos de azalactama como inhibidores de hpk1 |
| WO2021224818A1 (fr) * | 2020-05-08 | 2021-11-11 | Pfizer Inc. | Composés d'isoindolone en tant qu'inhibiteurs de hpk1 |
| JP7819176B2 (ja) * | 2020-08-03 | 2026-02-24 | ノバルティス アーゲー | ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| WO2024020458A1 (fr) * | 2022-07-20 | 2024-01-25 | Seal Rock Therapeutics, Inc. | Procédé de traitement de maladies ou de troubles d'organes avec des inhibiteurs d'ask1 |
| TW202547513A (zh) | 2024-05-06 | 2025-12-16 | 法商Ｇｅｎｆｉｔ公司 | 敗血症的治療 |
| WO2026057806A1 (fr) | 2024-09-13 | 2026-03-19 | Genfit | Forme posologique injectable de 2-[6-(4-cyclopropyl-4h-1,2,4-triazol-3-yl)-2-pyridyl]-5-morpholinocarbonyl-1-isoindolinone |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| TWI598347B (zh) * | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| PL2531501T3 (pl) * | 2010-02-03 | 2014-05-30 | Takeda Pharmaceuticals Co | Inhibitory kinazy 1 regulującej sygnał apoptotyczny |
| WO2012079022A1 (fr) * | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Dérivés de dioxopipéridinylphtalimide substitué |
| ES2617339T3 (es) * | 2010-12-16 | 2017-06-16 | Calchan Limited | Derivados de pirrolopirimidina inhibidores de ASK1 |
| MX2017003933A (es) * | 2014-09-24 | 2017-06-30 | Gilead Sciences Inc | Metodos de tratamiento de la enfermedad hepatica. |
| US10669242B2 (en) | 2016-06-10 | 2020-06-02 | Venenum Biodesign, LLC | Clostridium difficile toxin inhibitors |
| WO2018133866A1 (fr) | 2017-01-22 | 2018-07-26 | 福建广生堂药业股份有限公司 | Dérivé de pyridine en tant qu'inhibiteur d'ask1, son procédé de préparation et son utilisation |
| JP6754505B2 (ja) * | 2017-01-22 | 2020-09-09 | 福建広生堂薬業股▲ふん▼有限公司 | Ａｓｋ１阻害剤、その調製方法および使用 |
| EP3580224B1 (fr) | 2017-02-07 | 2022-07-13 | Biogen MA Inc. | Agents inhibiteurs d'ask1 |
| CN109071498B (zh) | 2017-02-16 | 2021-03-30 | 四川科伦博泰生物医药股份有限公司 | 激酶抑制剂及其制备方法和用途 |
| WO2018151830A1 (fr) | 2017-02-17 | 2018-08-23 | Fronthera U.S. Pharmaceuticals Llc | Inhibiteurs de kinase de régulation du signal apoptotique à base de pyridinyle |
| WO2018157277A1 (fr) | 2017-02-28 | 2018-09-07 | Eli Lilly And Company | Composés d'isoquinoléine et de naphtydrine |
| US11136324B2 (en) | 2017-03-03 | 2021-10-05 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Substituted imidazoles as apoptosis signal regulating kinase 1 inhibitors |
| JP2020512976A (ja) | 2017-03-27 | 2020-04-30 | ファーマケア，インク． | アポトーシスシグナル調節キナーゼ１（ａｓｋ１）阻害剤化合物 |
| EP3681499A4 (fr) * | 2017-09-13 | 2021-04-21 | D.E. Shaw Research, LLC | Composés utilisés comme inhibiteurs de ras et leur utilisation |
| WO2020006429A1 (fr) * | 2018-06-28 | 2020-01-02 | Hepatikos Therapeutics, Llc | Inhibiteurs d'isoindolin-1-one ask1 et leurs procédés d'utilisation |
-
2017
- 2017-06-16 JO JOP/2019/0221A patent/JOP20190221A1/ar unknown
-
2018
- 2018-04-03 TW TW107111742A patent/TWI779022B/zh active
- 2018-04-04 US US16/499,075 patent/US20210087167A1/en not_active Abandoned
- 2018-04-04 CU CU2019000080A patent/CU20190080A7/es unknown
- 2018-04-04 CA CA3059107A patent/CA3059107A1/fr active Pending
- 2018-04-04 PL PL18780760.7T patent/PL3606519T3/pl unknown
- 2018-04-04 ES ES18780760T patent/ES2992084T3/es active Active
- 2018-04-04 RU RU2019134679A patent/RU2019134679A/ru not_active Application Discontinuation
- 2018-04-04 PT PT187807607T patent/PT3606519T/pt unknown
- 2018-04-04 SI SI201831140T patent/SI3606519T1/sl unknown
- 2018-04-04 CR CR20190503A patent/CR20190503A/es unknown
- 2018-04-04 KR KR1020197032180A patent/KR102665145B1/ko active Active
- 2018-04-04 AU AU2018250217A patent/AU2018250217B2/en active Active
- 2018-04-04 EA EA201992299A patent/EA201992299A1/ru unknown
- 2018-04-04 SG SG11201909155V patent/SG11201909155VA/en unknown
- 2018-04-04 MA MA049047A patent/MA49047A/fr unknown
- 2018-04-04 MX MX2019012013A patent/MX394098B/es unknown
- 2018-04-04 FI FIEP18780760.7T patent/FI3606519T3/fi active
- 2018-04-04 JP JP2019553366A patent/JP7196093B2/ja active Active
- 2018-04-04 NZ NZ758345A patent/NZ758345A/en unknown
- 2018-04-04 CN CN201880037304.1A patent/CN110730661B/zh active Active
- 2018-04-04 WO PCT/US2018/026134 patent/WO2018187506A1/fr not_active Ceased
- 2018-04-04 DK DK18780760.7T patent/DK3606519T3/da active
- 2018-04-04 HU HUE18780760A patent/HUE068103T2/hu unknown
- 2018-04-04 PE PE2019001990A patent/PE20200009A1/es unknown
- 2018-04-04 EP EP18780760.7A patent/EP3606519B1/fr active Active
- 2018-04-05 AR ARP180100846A patent/AR111407A1/es active IP Right Grant
- 2018-05-03 US US15/970,587 patent/US10150755B2/en active Active
-
2019
- 2019-09-26 IL IL269711A patent/IL269711B/en unknown
- 2019-10-02 CL CL2019002810A patent/CL2019002810A1/es unknown
- 2019-10-03 PH PH12019502288A patent/PH12019502288A1/en unknown
- 2019-10-03 NI NI201900102A patent/NI201900102A/es unknown
- 2019-10-04 DO DO2019000255A patent/DOP2019000255A/es unknown
- 2019-10-23 CO CONC2019/0011708A patent/CO2019011708A2/es unknown
- 2019-10-31 EC ECSENADI201978393A patent/ECSP19078393A/es unknown
-
2024
- 2024-09-26 US US18/897,798 patent/US20250304552A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49047A (fr) | Composés inhibiteurs d'ask1 et utilisations associées | |
| EP3380101A4 (fr) | Composés inhibiteurs d'eif4-a et procédés associés | |
| EP3694861A4 (fr) | Composés hétérocycliques et leurs utilisations | |
| MA50256A (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
| EP3445365A4 (fr) | Inhibiteurs d'ezh2 et leurs utilisations | |
| MA44725A (fr) | Formulations d'un inhibiteur de lsd1 | |
| MA43862A (fr) | Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock | |
| MA52365A (fr) | Composés et leurs utilisations | |
| EP3481403A4 (fr) | Marqueurs de méthylation spécifiques d'une tumeur solide et utilisations de ces marqueurs | |
| EP3790861A4 (fr) | Compositions sénolytiques et utilisations associées | |
| MA46589A (fr) | Composés et utilisations de ces derniers | |
| MA52092A (fr) | Composés et leurs utilisations | |
| EP3728257A4 (fr) | Inhibiteurs de l'autotaxine et leurs utilisations | |
| EP3846807A4 (fr) | Composés d'imidazoquinoléine et leurs utilisations | |
| MA47420A (fr) | Composés inhibiteurs d'oga | |
| EP3509594A4 (fr) | Utilisations d'un inhibiteur d'homologue 2 de lysyl-oxydase | |
| EP3700934A4 (fr) | Composés et utilisations de ces composés | |
| EP3838900A4 (fr) | Composés de 3-aryloxy-3-aryl-propylamine et utilisations associées | |
| EP3494119A4 (fr) | Composés et compositions, et utilisations associées | |
| EP3880194A4 (fr) | Composés deutérés, compositions et utilisations | |
| EP3302490A4 (fr) | Inhibiteurs d'autotaxine et leurs utilisations | |
| EP3450444A4 (fr) | Composés de type crocine et utilisations correspondantes | |
| MA49006A (fr) | Inhibiteurs d'ip6k | |
| MA48956A (fr) | Composés mic-1 et utilisations associées | |
| EP3709998A4 (fr) | Nouveaux composés d'imidazopyrimidine et leurs utilisations |